Abstract
BackgroundOvarian cancer is the most lethal gynecologic malignancy. Most patients will experience disease recurrence after initial platinum-based chemotherapy. Although PRAP inhibitors showed clinical benefit in terms of progression free survival...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
